Drugs / IO-202
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05309187 | Apr 2022 → Mar 2024 | cancer | Immune-Onc Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04372433 | Sep 2020 → Jan 2025 | acute myeloid leukemia, chronic myelomonocytic leukemia | Immune-Onc Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-09-02 | Immune-Onc Therapeutics | Results Immune-Onc Therapeutics Announces Publication of Positive Phase 1 Results for IO-202 in CMML and AML in Blood Neoplasia immune-onc.com ↗
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced the publication of comprehensive data from its Phase 1 clinical study of IO-202, a first-in-class anti-LILRB4 antibody, in Blood Neoplasia. |
| 2024-12-09 | Immune-Onc Therapeutics | Results Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting immune-onc.com ↗
Responses were observed in patients across all subgroups, including those with proliferative disease, elevated blast counts, unfavorable mutations, and high symptom scores. |
| 2024-06-14 | Immune-Onc Therapeutics | Results Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress immune-onc.com ↗
The Phase 1b interim data continue to demonstrate that IO-202 is well tolerated. |
| 2024-05-14 | Immune-Onc Therapeutics | Results Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress immune-onc.com ↗
Phase 1b interim data demonstrate that IO-202 is well tolerated in combination with azacitidine. |
| 2024-02-21 | Immune-Onc Therapeutics | Regulatory Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by USFDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic MyelomonocyticLeukemia (CMML) immune-onc.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML). |
| 2023-06-07 | Immune-Onc Therapeutics | Results Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023 immune-onc.com ↗
IO-202 (anti-LILRB4) is well tolerated, with encouraging clinical responses in both monotherapy and combination therapy |
| 2022-02-17 | Immune-Onc Therapeutics | Regulatory Immune-Onc Therapeutics Receives FDA Fast Track Designation for IO-202, the First Anti-LILRB4 Myeloid Checkpoint Inhibitor, for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) immune-onc.com ↗
“We are pleased that the FDA has granted IO-202 Fast Track designation in recognition of its potential to improve outcomes for people with relapsed or refractory AML,” said Paul Woodard, Ph.D., chief medical officer of Immune-Onc. |
| 2022-01-31 | Immune-Onc Therapeutics | Regulatory Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors immune-onc.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for IO-202, a first-in-class antibody targeting leukocyte immunoglobulin-like receptor B4 (LILRB4, also known as ILT3), for the treatment of solid tumors. |
All press releases naming this drug 11 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IO-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04372433 ↗ |
| Modality | Monoclonal antibody | “IO-202 is a humanized immunoglobulin G1 monoclonal antibody” PMID 40919482 ↗ Jun 2025 |
| Route | Intravenous | “intravenous (IV) IO-202” NCT04372433 ↗ |
| Target | LILRB4 | “specificity for leukocyte immunoglobulin-like receptor B4 (LILRB4; ILT3)” PMID 40919482 ↗ Jun 2025 |